Tim Anderson, an analyst from Bank of America Securities, reiterated the Sell rating on Regeneron (REGN – Research Report). The associated price target was raised to $575.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tim Anderson’s rating is based on concerns surrounding the potential erosion of Eylea’s market share due to the introduction of biosimilars. Despite Regeneron’s strong Q4 performance, which exceeded revenue and earnings expectations, Anderson remains cautious about the company’s future earnings stability. The company provided guidance for 2025, focusing only on expenses without addressing potential revenue and earnings impacts from Eylea’s competition.
Anderson also notes that while Regeneron emphasizes its pipeline as a key growth driver, Eylea still represents a significant portion of its revenues, making its market dynamics crucial. The recent announcement of a dividend, while positively received, is considered a minor factor. With these factors in mind, Anderson reiterates an Underperform rating, reflecting concerns over faster-than-expected Eylea erosion and its implications on Regeneron’s earnings projections.
According to TipRanks, Anderson is a 4-star analyst with an average return of 9.4% and a 72.73% success rate. Anderson covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Pfizer, and Eli Lilly & Co.